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Oral Presentations 27amphotericin B therapy (p5 0.08) were not statistically significant.
There was a slight trend towards a higher rate of chronic GVHD in
patients with ES (p 5 0.11). However, after a median follow up of
9.5 years overall survival (48% with ES vs. 50% without ES; p 5
0.53) and transplant related mortality (21% vs. 17%; p 5 0.65)
did not differ between the two groups. Prednisolone (2 mg/kg/d)
was administered in 62% of children with ES.Conclusion: ES pre-
senting with fever, rash, weight gain and pulmonary symptoms
should be recognized as a frequent complication of allogeneic
HSCT after myeloablative conditioning in children. Treatment
withG-CSF and a high nucleated cell count of the graft predisposed
for the development of ES in this study. Overall survival and trans-
plant relatedmortality in this cohort were not affected by the occur-
rence of ES, possibly due to therapeutic intervention with
prednisolone in a high proportion of patients.66
EXCELLENT ENGRAFTMENT AND RAPID IMMUNE RECOVERY IN HAP-
LOIDENTICAL STEM CELL TRANSPLANTATION USING CD3/CD19 DE-
PLETED PERIPHERAL STEM CELL GRAFTS AFTER REDUCED
INTENSITY CONDITIONING
Bader, P.1, Soerensen, J.1, Koehl, U.1, Kreyenberg, H.1, Jarisch, A.1,
Weber, G.1, Sach, G.1, Willasch, A.1, Kuci, S.1, Tonn, T.2, Esser, R.1,
Klingebiel, T.1. 1 JW Goethe University Children’s Hospital, Frankfurt,
Germany; 2 Institut fu¨r Transfusionsmedizin, Frankfurt, Germany.
Transplantation of haploidentical stem cells has become a well
established treatment procedure in many children with malignant
and non malignant diseases. Positive enrichment of stem cells by
anti-CD34 magnetic micro beads provides a graft profoundly de-
pleted of T and B cells facilitating engraftment without inducing se-
vere GVHD. However, despite transplanting ‘‘mega doses’’ (.107/
kgBW) of stem cells, primary graft rejection and delayed immune
recovery associated with increased transplant related mortality re-
mained major obstacles. Grafts after depletion of CD3/CD19 cells
consist of remarkable amounts of effector cells which might help to
improve engraftment and immune reconstitution.
We report the results of our pilot study including 29 children and
adolescents (ALL, n5 10; AML, n5 3; RMA, n5 10; aplastic anae-
mia, n5 1, MDS, n5 2 and NBL/HB n5 2). All patients received
CD3/CD19 depleted peripheral stem cell grafts containing a me-
dian number of 7.46/kgBW CD341 cells. Grafts also contained
NK-cells (median number: 14.36/kgBW), dendritic cells, precursor
T-cells and mono-/granulocytes (median number: 423.46/kgBW).
All patients but two received a reduced conditioning regimen with
FLU-MEL-THIO and short course of OKT-3. All twenty-nine pa-
tients achieved rapid engraftment at day 14 and 156 days, respec-
tively. Immune recovery was excellent with a median time to
achieve more than 100 CD31 and CD41 cells/ml was 61.0 and
63.5 days, respectively. Five/29 patients developed acute GvHD
grade II and grade III (n 5 2). Fourteen out of 29 patients (48%)
are alive and in CR with a median follow-up of 282 days (range:
42–968 days). Two heavily pre-treated patients died due to TRM.
Ten patients died due to relapse of their underlying disease. Two
patients died of Adeno virus infection. In conclusion, haploidentical
transplantation using CD3/CD19 depleted grafts seems to be a fea-
sible strategy to overcome the high risk of graft rejection and to im-
prove immune reconstitution.67
CLINICAL OUTCOMES OF ADOLESCENT PATIENTS UNDERGOING HEMA-
TOPOIETIC STEM CELL TRANSPLANT
Midura, B.2, Lehmann, L.1, Duncan, C.1. 1 Dana-Farber Cancer Insti-
tue, Boston, MA; 2 Children’s Hospital, Boston, Boston, MA.
There is concern that the outcome for adolescent oncology pa-
tients is worse than that of younger patients with the same disease.
The effect of patient age on outcome following pediatric allogeneic
hematopoietic stem cell transplant (HSCT) has not been well de-
scribed. We retrospectively reviewed the medical records of all pe-diatric allogeneicHSCTpatients at our institution between January
1, 2001 and December 31, 2006. We investigated survival, cause of
death, and occurrence of graft-versus-host disease (GVHD) in pa-
tients 15–21 years old at time of HSCT compared with patients
10–14.9 years old at transplant. 127 patients greater than 10 years
old (10–14.9 years 5 73 patients; greater than 15 years 5 54 pa-
tients) were transplanted during the study period. Indications for
HSCT were similar in both groups (see table). 53.4% of patients
in the younger group received unrelated donor (URD) transplants
compared with 48.1% in the older group. A greater percentage of
patients in the younger group received cells from a donor matched
at less than 6 HLA loci (20.5% versus 9.3%). There was no statisti-
cally significant difference in the incidence of chronic GVHD
(younger 42.5%, older 46.2%). Patients greater than 15 years old
had a higher risk of mortality compared to younger patients (odds
ratio5 1.85). Relapse was the cause of death (COD) in 13.7%of pa-
tients in the younger group and 16.7% of patients in the older
group. Transplant related mortality (TRM) was greater in the older
group (younger 16.4%, older 27.8%). Older adolescents had in-
creased toxicity resulting in increased mortality following HSCT
compared to younger adolescents with similar underlying disease
and transplant characteristics. Further study is needed to better un-
derstand these findings and their potential impact on the care of ad-
olescent stem cell transplant patients.
Younger Adolescents Compared with Older Adolescents
Age 10–14.9 Age .15
years (n5 73) years (n5 54)Death 22 (30.1%) 24 (44.4%)
Cause of death: Relapse 10 9
Cause of death: TRM 12 15
Chronic GVHD 31 (42.5%) 25 (46.2%)
Related donor 34 (46.6%) 28 (51.9%)
Source: bone marrow 65 (89%) 51 (94.6%)
Acute lymphoblastic 24 (32.9%) 14 (25.9%)
Acute myelogenous leukemia/
myelodysplasia26 (35.6%) 20 (37%)Chronic myelogenous
leukemia8 (11%) 8 (14.8%)Nonmalignant hematologic
disease9 (12.3%) 10 (18.5%)Other 6 (8.2%) 2 (3.7%)68
GENE THERAPY FOR ADENOSINE DEAMINASE (ADA)-DEFICIENT SE-
VERE COMBINED IMMUNE DEFICIENCY (SCID): COMPARATIVE RE-
SULTS WITH OR WITHOUT PEG-ADA WITHDRAWAL AND
MYELOSUPPRESSIVE CHEMOTHERAPY
Podsakoff, G.1, Engel, B.C.1, Sokolic, R.2, Carbonaro, D.A.1, Muul, L.2,
Garabedian, E.2, Ireland, J.1, Hershfield, M.3, Wayne, A.4, Dunbar, C.5,
Candotti, F.2, Kohn, D.B.1. 1 Childrens Hospital Los Angeles, Los Angeles,
CA; 2 National Institutes of Health, Bethesda, MD; 3 Duke University
Medical Center, Durham, NC; 4 National Institutes of Health, Bethesda,
MD; 5 National Institutes of Health, Bethesda, MD.
In 2001–2002, we treated 4 ADA-SCIDpatients in a gene therapy
(GTx) clinical trial evaluating the efficacy of 2 different retroviral
vectors while continuing enzyme replacement with pegylated bo-
vine ADA (PEG-ADA). No cytoreductive conditioning was used.
All patients have been monitored for 6 years. No treatment-related
SAE occurred. A mild transient elevation in absolute lymphocyte
count (ALC) was seen in 2 patients early post-treatment, however,
no durable immunologic changes were observed. Low levels (0.1–
0.7%) of vector-marked PBMC persist for at least five years in 2 pa-
tients treated at the age of 4–5 years. All patients remain on PEG-
ADA, prophylactic antibiotics and IVIg. In 2004, we revised the
protocol to facilitate engraftment and selective advantage of gene-
corrected cells by withdrawing PEG-ADA and giving busulfan
(75 mg/m2) before GTx. In November 2005, a 1st patient was
treated who developed unexpected prolonged bone marrow (BM)
28 Oral Presentationsaplasia. Cytogenetics revealed trisomy 8 mosaicism, present on
a BM specimen obtained pre-GTx (Blood 2007; 109:503). Our
2nd patient enrolled in January 2007. He received 5  106
CD341 cells/kg that showed 40–200U of ADA activity after trans-
duction (normal range 58–128). Over 6 months, this patient showed
a slow increase in ALC (up to 750/mcL) and lymphocyte function.
PBMC ADA activity has been up to 50U. The dAXP level has de-
creased to below 10%, levels typically seen after allogeneic BM
transplant. A 3rd patient was treated in May 2007 and received 2
 106 CD341 cells/kg with ADA activity of 7–87U. Over three
months, lymphocyte function has increased over pretreatment level.
PBMC ADA activity has been up to 24U and the dAXP levels have
decreased to less than 10%. Both patients have been off PEG-ADA
since 2 weeks pre-GTx and had mild post-GTx courses, with no
documented infection, and no need for blood products. AST and
ALT rose to 200 U/L, and then resolved, an effect attributed to
PEG-ADA withdrawal or busulfan administration. Without mye-
loid growth factors, times to neutrophil count above 500/mcL
were 36 and 45 days. These data are consistent with the positive re-
sults of GTx for ADA-SCID obtained inMilan and London and di-
rectly show that PEG-ADA withdrawal and reduced conditioning
improve the outcome of GTx for ADA-SCID. Longer follow-up
should allow us to study engraftment of cells containing vector-spe-
cific sequences and to conclude if either vector contributes more to
recovery of lymphoid immunity.69
SIROLIMUS (SRL)-BASED GVHD PROPHYLAXIS AFTER TBI/TT/CY ALLO-
GENEIC HSCT IN PEDIATRIC PATIENTS WITH HR ALL: RESULTS OF
A MULTI-INSTITUTIONAL PILOT STUDY
Pulsipher, M.A.1, Wall, D.2, Goyal, R.3, Grupp, S.4, Bunin, N.4. 1 Uni-
versity of Utah/Primary Children’s Medical Center, Salt Lake City, UT;
2 Methodist Children’s Hospital, San Antonio, TX; 3 Children’s Hospital
of Pittsburgh, Pittsburgh, PA; 4 Children’s Hospital of Philadelphia, Phil-
adelphia, PA.
Relapse andNRMafter allogeneic HSCT remain significant bar-
riers to success in treating very high-risk ALL. Sirolimus (SRL) has
been shown to have cytotoxic activity against human ALL at serum
levels used for immune suppression. We hypothesized that the ad-
dition of SRL to a tacrolimus (TAC)/methotrexate (MTX) GVHD
prophylaxis regimen would decrease relapse after HSCT for ALL.
This multi-institutional pilot trial included a preparative regimen
of fractionatedTBI (1200 cGy), thiotepa (5mg/kg/d 2) and cyclo-
phosphamide (60mg/kg 2). Pts received IVTAC (start d-2, target
5–10 ng/mL), PO SRL (start d0, target 3–12 ng/mL), and IVMTX
(5mg/m2, d1 1,13, and16 plus d1 11 for UDBM/PBSC). TAC
was tapered between d 1 42–96 for MSD and d 1 100–180 for
others. SRL was tapered over 4 wks starting 6 m after transplant.
This report includes 50 pediatric pts (med age 9 (1–21)) with
a med f/u of 17 m (5–50). Immunophenotypes included 38 B-line-
age and 12 T-lineage. Risk groups included 12 pts in high risk
(HR) CR1, 5 in HR isolated extramedullary (IEM) relapse, 8 in
very early relapsing (VER,\18 m) CR2, 6 in early relapsing (ER,
18–36 m) CR2, 10 with late relapsing (LR, $36 m) CR2, and 9 in
CR3. Stem cell sources included 22MSD-BM, 25 UCB, and 3 UD.
Results: 2 yr EFS for the entire cohort was 72% (SE 8.1) and did
not differ by stem cell source. 2 yr EFS by risk groups is outlined in
the table below, showing better than anticipated survival in all sub-
groups. Within the HR CR2 subgroups (BM relapse\36 m from
diagnosis), T-lineage VER CR2 pts had worse 2 yr EFS compared
to B-lineage VERCR2 and B- and T-lineage ERCR2 pts (2 yr EFS
20% vs. 64%, p5 0.057). One recipient of CB failed to engraft and
a second relapsed prior to engraftment. All remaining pts engrafted
at a median of 21 (13–31), 28 (16–62), and 20 (17–21) days forMSD,
CB, and UD, respectively. aGVHD grade II-IV and III-IV oc-
curred in 40 and 21% of patients, while cGVHD occurred in
30%.NRMoccurred in 5 patients (10%: 4 CB, 1MSD). Significant
toxicities included VOD (5 pts, reversible in 3, part of fatal MSOF
in 2 in the context of bacterial (1) and viral (1) sepsis), non-fatal
HUS (2 pts), and non-fatal IPS (1 pt). In summary, SRL-based
GVHD prophylaxis after TBI/TT/Cy allogeneic HSCT results
in high rates of engraftment, low NRM, and improved 2 yr EFSin every risk group except T-lineage VER in CR2. A phase 3 trial
in the COG for ALL patients in CR2 comparing TAC/MTX
with TAC/MTX/SRL after TBI/TT/Cy allogeneic HSCT is on-
going.2 yr EFS by Risk Group
ALL Risk ALL HR ALLVER ALL ER ALL LR ALL IEMGroup CR1 CR2 CR2 CR2 ALL CR3 CR22 yr EFS (±SE) 92% (±8) 38% (±17) 60% (±22) 90% (±10) 65% (±17) 100%70
IMPROVED OUTCOME FOR TRANSPLANTATION OF PEDIATRIC PA-
TIENTSWITHNON-MALIGNANT DISORDERSWITH UNWASHED PLASMA
DEPLETED CORD BLOOD (PD CB)
Rosenthal, J.1, Jaing, T.-H.2, Chan, L.L.3, Eames, G.4, Graham, M.5,
Tan, A.M.6, Lin, H.P.7, Nademanee, A.1, Karanes, C.1, Wang, B.8,
Chow, T.8, Tan, P.9, Gjertson, D.10, Petz, L.8, Chow, R.8,11,
Forman, S.1. 1 City of Hope National Medical Center, Duarte, CA;
2 Chang Gung University & Children’s Hospital, Linkou, Taiwan; 3 Uni-
versity of Malaya Medical Center, Kuala Lumpur, Malaysia; 4 Cook Chil-
dren’s Hospital, Fort Worth, TX; 5 University of Arizona Medical Center,
Tucson, AZ; 6 KK Women & Children’s Hospital, Singapore; 7 Subang
Jaya Medical Center, Malaysia; 8 StemCyte International Cord Blood
Center, Arcadia, CA; 9 Mount Elizabeth Hospital, Singapore; 10 UCLA
School of Public Health, Los Angeles, CA; 11 StemCyte Taiwan National
Medical Center, Linkou, Taiwan.
CB is an attractive source for unrelated transplantation of benign
indications because of the potentially better availability for minori-
ties. Since most patients are children, cell dosage is less of a limita-
tion; however, cell dose is still important. We have consistently
employed 3 strategies to maximize cell dose - plasma depletion pro-
cessing without red blood cell reduction, no post-thaw wash (NW),
and the use of double cords (2X) when necessary. A retrospective
CIBMTR-audited analysis was performed on all 87 pediatric
(\50 kg) patients with non-malignant disorders transplanted with
98 PDCB products (15 double cords) at 21 US and 16 international
institutions. Weight was used instead of age to emphasize impor-
tance of cell dose. The disease breakdowns were: 40 thalassemias,
12 congenital immunodeficiency syndromes, 9 aplastic anemia, 5
Hurler syndrome, 4 osteopetrosis, 2 chronic granulomatous dis-
ease, 2 familial hemophagocytosis, 2 Fanconi anemia, 2 inherited
metabolic disorders, and 9 for other disorders. Transplant charac-
teristics: median age 4 years (range 0.1–27); median weight 16 kg
(range 4–49); male 54%; HLA ABDR matches: 18–6/6; 32–5/6;
30–4/6; 6–3/6, 1–2/6; median pre-freeze TNC dose 9.8  107/kg;
median post-thaw TNC dose as reported by TC 6.7  107/kg; me-
dian pre-freeze CD341 dose 3.5  105/kg; transplants outside of
U.S.- 54 (62%); non-myeloablative - 13 (15%); 34% post-thaw
washed (W) and 66% infused without post-thaw wash (NW) of
those with known post-thaw status. Median follow-up time was
220 days (range 8–1,448 days). With no unevaluable cases, cumula-
tive incidence was used to estimate engraftment, acute and chronic
graft-versus-host disease (aGvHD and cGvHD), and Kaplan-Meier
estimates were used for all other outcome. As shown below, forego-
ing post-thaw wash improved engraftment, TRM and survival, and
significantly reduced extensive cGvHD. This series is unusual in its
cell dose, high even for pediatric patients, and shows that unrelated
PDCB transplantation can be performed safely and effectively, with
outstanding neutrophil (92 6 9%) and platelet engraftment (85 6
9%), extensive cGvHD (3 6 3%), overall (90 6 4%) and disease-
free survival (78 6 6%) rates achieved when post-thaw wash is not
employed, even in a diverse population of pediatric patients with
non-malignant disorders.
